AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC
-
- STATUS
- Recruiting
-
- End date
- Dec 28, 2024
-
- participants needed
- 250
-
- sponsor
- Blueprint Medicines Corporation
Summary
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for patients with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease. Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.
Details
| Condition | Bronchogenic Carcinoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Pulmonary Disease, Adenocarcinoma, Adenocarcinoma, Cancer, Respiratory Tract Diseases, Respiratory Tract Neoplasm, Thoracic Neoplasms, Carcinoma, Lung Neoplasm, Bronchial disorder, head and neck cancer, head and neck cancer, Neoplasms, Nerve Tissue, Germ cell tumor, Neoplasms by Histologic Type, Neoplasms by Site, RET-fusion Non Small Cell Lung Cancer |
|---|---|
| Age | 18-100 years |
| Treatment | Carboplatin, Pembrolizumab, Pemetrexed, Gemcitabine, Cisplatin, Pralsetinib |
| Clinical Study Identifier | NCT04222972 |
| Sponsor | Blueprint Medicines Corporation |
| Last Modified on | 19 February 2024 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Add a private note
- Select a piece of text from the left.
- Add notes visible only to you.
- Send it to people through a passcode protected link.
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.